Rapt Therapeutics Stock Buy Hold or Sell Recommendation

RAPT Stock  USD 1.12  0.03  2.75%   
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding RAPT Therapeutics is 'Buy'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell RAPT Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for RAPT Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
  
Check out RAPT Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.
Note, we conduct extensive research on individual companies such as RAPT and provide practical buy, sell, or hold advice based on investors' constraints. RAPT Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

Execute RAPT Therapeutics Buy or Sell Advice

The RAPT recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on RAPT Therapeutics. Macroaxis does not own or have any residual interests in RAPT Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute RAPT Therapeutics' advice using the current market data and latest reported fundamentals.

Time Horizon

2  Years

Risk Tolerance

I am willing to take any risk
Execute Advice
Sell RAPT TherapeuticsBuy RAPT Therapeutics
JavaScript chart by amCharts 3.21.15
Buy

Market Performance

InsignificantDetails

Volatility

Abnormally volatileDetails

Hype Condition

Under hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

LowDetails

Economic Sensitivity

Hyperactively responds to market trendsDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

BuyDetails

Financial Strenth (F Score)

HealthyDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon RAPT Therapeutics has a Risk Adjusted Performance of 0.044, Jensen Alpha of 0.8172, Total Risk Alpha of 1.26, Sortino Ratio of 0.1289 and Treynor Ratio of 0.1411
We provide trade recommendations to complement the recent expert consensus on RAPT Therapeutics. Our dynamic recommendation engine exercises a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available now. To make sure RAPT Therapeutics is not overpriced, please check all RAPT Therapeutics fundamentals, including its cash per share, as well as the relationship between the short ratio and total asset . Given that RAPT Therapeutics is a hitting penny stock territory we advise to closely look at its price to book.

RAPT Therapeutics Trading Alerts and Improvement Suggestions

RAPT Therapeutics is way too risky over 90 days horizon
RAPT Therapeutics may become a speculative penny stock
RAPT Therapeutics appears to be risky and price may revert if volatility continues
Net Loss for the year was (116.8 M) with profit before overhead, payroll, taxes, and interest of 1.53 M.
RAPT Therapeutics currently holds about 207.34 M in cash with (97.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Over 96.0% of the company shares are owned by institutional investors
Latest headline from gurufocus.com: FMR LLC Significantly Reduces Stake in RAPT Therapeutics Inc

RAPT Therapeutics Returns Distribution Density

The distribution of RAPT Therapeutics' historical returns is an attempt to chart the uncertainty of RAPT Therapeutics' future price movements. The chart of the probability distribution of RAPT Therapeutics daily returns describes the distribution of returns around its average expected value. We use RAPT Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of RAPT Therapeutics returns is essential to provide solid investment advice for RAPT Therapeutics.
Mean Return
0.69
Value At Risk
-9.09
Potential Upside
9.09
Standard Deviation
14.42
   Return Density   
JavaScript chart by amCharts 3.21.15-102.0-76.18-50.36-24.530.023.4949.5975.69101.79127.89VARUpside 0.001600.001650.001700.001750.001800.001850.00190
JavaScript chart by amCharts 3.21.15GOOGLE
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of RAPT Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

RAPT Stock Institutional Investors

The RAPT Therapeutics' institutional investors refer to entities that pool money to purchase RAPT Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
Shares
Affinity Asset Advisors, Llc2024-12-31
1000 K
Federated Hermes Inc2024-09-30
800 K
D. E. Shaw & Co Lp2024-12-31
770 K
Millennium Management Llc2024-12-31
737.7 K
Geode Capital Management, Llc2024-12-31
716.9 K
State Street Corp2024-12-31
699.2 K
Euclidean Capital Llc2024-12-31
657.9 K
Kingdon Capital Management Llc2024-12-31
575 K
Two Sigma Advisers, Llc2024-12-31
503.7 K
Tcg Crossover Management, Llc2024-12-31
13.1 M
Rtw Investments, Llc2024-12-31
11.8 M
Note, although RAPT Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

RAPT Therapeutics Cash Flow Accounts

202020212022202320242025 (projected)
Investments(87.0M)(80.6M)(44.6M)42.2M38.0M39.9M
Change In Cash(52.5M)(891K)14.9M8.5M9.8M10.3M
Free Cash Flow(40.9M)(61.8M)(71.6M)(98.2M)(88.4M)(83.9M)
Depreciation1.1M996K1.0M1.2M1.1M952.3K
Other Non Cash Items248K1.5M2.1M(4.1M)(3.7M)(3.5M)
Capital Expenditures398K755K845K1.1M1.0M986.9K
Net Income(52.9M)(69.2M)(83.8M)(116.8M)(105.1M)(99.9M)
End Period Cash Flow24.9M24.0M38.9M47.5M42.7M37.0M
Change To Netincome2.1M8.4M11.5M11.9M13.7M14.4M

RAPT Therapeutics Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to RAPT Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that RAPT Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a RAPT stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over Dow Jones
0.82
β
Beta against Dow Jones4.79
σ
Overall volatility
15.17
Ir
Information ratio 0.05

RAPT Therapeutics Volatility Alert

RAPT Therapeutics is displaying above-average volatility over the selected time horizon. RAPT Therapeutics is a potential penny stock. Although RAPT Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in RAPT Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on RAPT instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

RAPT Therapeutics Fundamentals Vs Peers

Comparing RAPT Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze RAPT Therapeutics' direct or indirect competition across all of the common fundamentals between RAPT Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as RAPT Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of RAPT Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing RAPT Therapeutics by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare RAPT Therapeutics to competition
FundamentalsRAPT TherapeuticsPeer Average
Return On Equity-0.8-0.31
Return On Asset-0.47-0.14
Current Valuation61.66 M16.62 B
Shares Outstanding132.01 M571.82 M
Shares Owned By Insiders0.49 %10.09 %
Shares Owned By Institutions96.42 %39.21 %
Number Of Shares Shorted2.81 M4.71 M
Price To Book1.62 X9.51 X
Price To Sales411.22 X11.42 X
Gross Profit1.53 M27.38 B
EBITDA(125.85 M)3.9 B
Net Income(116.8 M)570.98 M
Cash And Equivalents207.34 M2.7 B
Cash Per Share6.99 X5.01 X
Total Debt6.91 M5.32 B
Debt To Equity0.04 %48.70 %
Current Ratio15.97 X2.16 X
Book Value Per Share2.74 X1.93 K
Cash Flow From Operations(97.05 M)971.22 M
Short Ratio3.42 X4.00 X
Earnings Per Share(2.78) X3.12 X
Target Price6.0
Number Of Employees7018.84 K
Beta0.031-0.15
Market Capitalization143.89 M19.03 B
Total Asset173.33 M29.47 B
Retained Earnings(484.68 M)9.33 B
Working Capital139.95 M1.48 B
Current Asset17 K9.34 B
Current Liabilities167 K7.9 B
Net Asset173.33 M
Note: Acquisition by Wong Brian Russell of 1746000 shares of RAPT Therapeutics at 1.14 subject to Rule 16b-3 [view details]

RAPT Therapeutics Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as RAPT . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About RAPT Therapeutics Buy or Sell Advice

When is the right time to buy or sell RAPT Therapeutics? Buying financial instruments such as RAPT Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having RAPT Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Insurance Providers Thematic Idea Now

Insurance Providers
Insurance Providers Theme
Companies providing all types of insurance and insurance services. The Insurance Providers theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Providers Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for RAPT Stock Analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.